Orbem

Orbem GmbH is headquartered in Munich and was founded in 2019 as a spin-off of the Munich Institute of Biomedical Engineering at the Technical University of Munich. Its co-founders are Pedro Gómez (CEO), Maria Laparidou (CSO) and Miguel Molina (CPTO). The company pairs magnetic resonance imaging with artificial intelligence to examine biological material from the inside, without cutting or damaging it, starting in poultry and aiming at other foods and, in time, human health. Its most mature product is Genus Focus, developed with Vencomatic Group, which determines an embryo's sex in the egg on day 11 or 12 of incubation without piercing the shell, in under a second per egg. It is one of the in-ovo sexing technologies that make it possible to avoid culling male chicks. Genus Scale instead identifies unfertilised eggs before incubation. According to the company, more than 170 million eggs had been scanned by January 2026 and about 250 million by September 2026, with 11 customers in six countries across Europe and the United States. Fruit inspection followed in 2026: with the Spanish grower JimboFresh, Orbem announced the Genus Echo system in May to check watermelons from skin to core. In healthcare, the company so far speaks only of building a large biological dataset for AI models. Regulation is pushing the market: according to Orbem's newsroom, Germany and France banned chick culling in 2022, Italy will do so from 1 January 2027, and the European Commission plans EU-wide legislation by the end of 2026. On funding, Orbem announced a EUR 30 million Series A of debt and equity in October 2023, led by 83North, and a EUR 55.5 million Series B in January 2026, led by Innovation Industries with Supernova Invest, aimed notably at entering the US market, where it opened a Houston office in 2025. In the Series B release the company describes itself as already profitable.